Milestone Pharmaceuticals Total Current Assets Over Time
| MIST Stock | USD 1.84 0.01 0.54% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Milestone Pharmaceuticals Performance and Milestone Pharmaceuticals Correlation. Milestone |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Milestone Pharmaceuticals. If investors know Milestone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Milestone Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.80) | Quarterly Revenue Growth (1.00) | Return On Assets (0.33) | Return On Equity (1.34) |
The market value of Milestone Pharmaceuticals is measured differently than its book value, which is the value of Milestone that is recorded on the company's balance sheet. Investors also form their own opinion of Milestone Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Milestone Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Milestone Pharmaceuticals' market value can be influenced by many factors that don't directly affect Milestone Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Milestone Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Milestone Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Milestone Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Current Assets Analysis
Compare Milestone Pharmaceuticals and related stocks such as DiaMedica Therapeutics, Seres Therapeutics, and Inhibikase Therapeutics Total Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMAC | 27.6 K | 2.7 M | 2.5 M | 2.6 M | 266 K | 208.1 K | 1.9 M | 1.5 M | 18 M | 8.8 M | 27.9 M | 45.4 M | 33.8 M | 53.7 M | 56.4 M |
| MCRB | 6.2 M | 6.2 M | 6.2 M | 1.7 M | 114.2 M | 207.6 M | 198.4 M | 155.1 M | 92.7 M | 100.2 M | 268.8 M | 303.6 M | 194.8 M | 175.4 M | 166.7 M |
| IKT | 80.2 K | 80.2 K | 80.2 K | 80.2 K | 80.2 K | 80.2 K | 80.2 K | 198.1 K | 1.3 M | 35.4 K | 14.8 M | 42.5 M | 24.4 M | 14.2 M | 13.4 M |
| ONCY | 4.6 M | 35.6 M | 21.7 M | 27.7 M | 16.7 M | 26.9 M | 14.4 M | 17.8 M | 14.5 M | 18.9 M | 33.7 M | 44.9 M | 35.7 M | 38.2 M | 28 M |
| SCPH | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 39.7 M | 119.9 M | 91.9 M | 75.6 M | 107.8 M | 78.3 M | 123.3 M | 92.9 M | 89.4 M |
| XFOR | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 5.7 M | 80.8 M | 35.1 M | 129.3 M | 83.3 M | 87.9 M | 128.7 M | 122.1 M | 83.3 M |
| DAWN | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 45.1 M | 289.4 M | 347.9 M | 375.3 M | 238.7 M |
| HOOK | 70 M | 70 M | 70 M | 70 M | 70 M | 70 M | 70 M | 70 M | 62.3 M | 128 M | 171.5 M | 102.1 M | 147.2 M | 147.1 M | 130.2 M |
| SPRO | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 11.9 M | 87.3 M | 115.4 M | 82 M | 126.9 M | 157.9 M | 109.1 M | 131.2 M | 101.2 M |
| BOLT | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 35.9 M | 25.4 M | 189.2 M | 172.7 M | 105.7 M | 99.5 M |
| CHRS | 24.8 M | 24.8 M | 24.8 M | 45.7 M | 150.4 M | 158.2 M | 124.9 M | 126.9 M | 72.4 M | 374.7 M | 790.4 M | 633.5 M | 416.7 M | 475.6 M | 311.1 M |
| NAMS | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 9.2 M | 58.9 M | 448.1 M | 346.8 M | 237.3 M |
| IVA | 16.2 M | 16.2 M | 16.2 M | 16.2 M | 21.5 M | 28.6 M | 41.2 M | 67.2 M | 71.6 M | 48.9 M | 133 M | 115.6 M | 106.4 M | 48.2 M | 69.8 M |
| CGEM | 12.7 K | 12.7 K | 12.7 K | 12.7 K | 6.3 K | 118 | 3.4 K | 34.2 M | 34.2 M | 100.1 M | 212.3 M | 296.6 M | 474.5 M | 480.2 M | 504.2 M |
| CMPX | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M | 26.2 M | 50.2 M | 147.1 M | 194.8 M | 153.9 M | 115.7 M |
Milestone Pharmaceuticals and related stocks such as DiaMedica Therapeutics, Seres Therapeutics, and Inhibikase Therapeutics Total Current Assets description
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.My Equities
My Current Equities and Potential Positions
| Milestone Pharmaceuticals | MIST |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Quebec; Canada |
| Exchange | NASDAQ Exchange |
USD 1.84
Additional Tools for Milestone Stock Analysis
When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.